Related Experiment Video
Updated: Jul 29, 2026
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Hyaluronic Acid Modified Nanostructured Lipid Carrier for Targeting Delivery of Kaempferol to NSCLC: Preparation,
Yufei Ma1, Jinli Liu2, Xinyu Cui3
1Department of Pharmacy, Mudanjiang Medical University, Mudanjiang 157000, China.
Abstract:
Lung cancer seriously threatens the health of human beings, with non-small cell lung cancer (NSCLC) accounting for 80%. Nowadays, the potential position of nano-delivery in treating cancer has been the subject of continuous research. The present research aimed to prepare two molecular weight hyaluronic acid (HA)-modified kaempferol (KA)-loaded nanostructured lipid carriers (HA-KA-NLCs) by the method of melting ultrasonic and electrostatic adsorption, and to assess the antitumor effect of the preparations on A549 cells. The characterization and safety evaluation of the preparations illustrated that they are acceptable for drug delivery for cancer. Subsequently, differential scanning calorimetry (DSC) curve and transmission electron microscopy (TEM) images indicated that the drug was adequately incorporated in the carrier, and the particle appeared as a sphere. Moreover, HA-KA-NLC showed predominant in vitro antitumor effects, inhibiting proliferation, migration, and invasion, promoting apoptosis and increasing cellular uptake of A549 cells. Otherwise, the Western blot assay revealed that preparations could activate epithelial-mesenchymal transition (EMT)-related signaling pathways and modulate the expression of E-cadherin, N-cadherin, and Vimentin in A549 cells. Our present findings demonstrated that HA-KA-NLC could be considered as a secure and effective carrier for targeted tumor delivery and may have potential application prospects in future clinic therapy of NSCLC.
Insights
Hyaluronic acid-modified kaempferol nanostructured lipid carriers (HA-KA-NLCs) show promise for non-small cell lung cancer (NSCLC) therapy. These nano-delivery systems effectively inhibit cancer cell growth and invasion in vitro.
Area of Science:
- Nanotechnology
- Oncology
- Materials Science
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
- Nano-delivery systems offer potential for targeted cancer therapy.
- Kaempferol (KA) is a natural compound with potential anticancer properties.
Purpose of the Study:
- To prepare and characterize hyaluronic acid (HA)-modified kaempferol-loaded nanostructured lipid carriers (HA-KA-NLCs).
- To evaluate the in vitro antitumor effects of HA-KA-NLCs on A549 lung cancer cells.
- To investigate the mechanism of action of HA-KA-NLCs in NSCLC cells.
Main Methods:
- Preparation of HA-KA-NLCs using melting ultrasonic and electrostatic adsorption.
- Characterization of HA-KA-NLCs using DSC and TEM.
- In vitro assessment of antitumor activity, including proliferation, migration, invasion, apoptosis, and cellular uptake assays.
- Western blot analysis to evaluate EMT-related signaling pathways.
Main Results:
- HA-KA-NLCs were successfully prepared, characterized as spherical, and deemed safe for drug delivery.
- HA-KA-NLCs demonstrated significant in vitro antitumor effects on A549 cells.
- These effects included inhibition of proliferation, migration, and invasion; promotion of apoptosis; and increased cellular uptake.
- Western blot analysis indicated modulation of EMT markers (E-cadherin, N-cadherin, Vimentin) and activation of related pathways.
Conclusions:
- HA-KA-NLCs represent a secure and effective nano-carrier for targeted lung cancer therapy.
- The developed nano-delivery system shows potential for future clinical application in NSCLC treatment.
- Further research is warranted to explore the in vivo efficacy and therapeutic potential of HA-KA-NLCs.
More Related Videos
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers